Cargando…

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis

BACKGROUND: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuda, Yoshinori, Omoto, Seitaro, Taniura, Takehito, Shouzu, Akira, Nomura, Shosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835142/ https://www.ncbi.nlm.nih.gov/pubmed/27110135 http://dx.doi.org/10.2147/IJGM.S102070

Ejemplares similares

Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)
por: Nomura, Shosaku, et al.
Publicado: (2018)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients
por: Nomura, Shosaku, et al.
Publicado: (2012)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema
por: Nishizawa, Tohru, et al.
Publicado: (2015)

Extracellular Vesicle-Related Thrombosis in Viral Infection
por: Nomura, Shosaku, et al.
Publicado: (2020)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma, Surendra Kumar, et al.
Publicado: (2016)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

State laws and policies to reduce opioid-related harm: A qualitative assessment of PDMPs and naloxone programs in ten U.S. States
por: Whitmore, Christine C., et al.
Publicado: (2018)

Genetic analysis of HLA, NA and HPA typing in type 2 diabetes and ASO
por: Nomura, S, et al.
Publicado: (2006)

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin
por: Minezumi, Takumi, et al.
Publicado: (2018)

Exanthematous Drug Eruption as a Side Effect of Teneligliptin
por: Sunil, Krupa A., et al.
Publicado: (2021)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Teneligliptin and “Thorough QTc study”: thorough enough?
por: Ghosal, Samit
Publicado: (2019)

Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022)

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
por: Homma, Koichiro, et al.
Publicado: (2017)

Teneligliptin-induced hair loss: A case report
por: Agrawal, Prabhat K., et al.
Publicado: (2020)

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions
por: De Nigris, Valeria, et al.
Publicado: (2017)

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation
por: Nomura, Shosaku, et al.
Publicado: (2016)

Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
por: Kutoh, Eiji, et al.
Publicado: (2014)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
por: Ceriello, Antonio, et al.
Publicado: (2019)

SAT-173 Antiproliferative Effect of Teneligliptin on Atherosclerosis in Vascular Smooth Muscle Cell
por: Moon, Shinje, et al.
Publicado: (2019)

Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
por: Kumar, Amit, et al.
Publicado: (2019)

Diffuse erythematous rash after teneligliptin therapy: A case report
por: Agrawal, Prabhat, et al.
Publicado: (2018)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
por: Fushimi, Yoshiro, et al.
Publicado: (2020)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh, Sujoy, et al.
Publicado: (2016)

Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability in vivo and in vitro
por: Zhang, Lei, et al.
Publicado: (2020)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
por: Tandon, Tanya, et al.
Publicado: (2019)

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)
por: Ghosh, Sujoy, et al.
Publicado: (2020)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

The Effect of PAI-1 Gene Variants and PAI-1 Plasma Levels on Development of Thrombophilia in Patients With Klinefelter Syndrome
por: Erkal, Burcin, et al.
Publicado: (2018)

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition
por: Sillen, Machteld, et al.
Publicado: (2020)

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis
por: Mitra, Asis, et al.
Publicado: (2020)

Teneligliptin Co-Infusion Alleviates Morphine Tolerance by Inhibition of Spinal Microglial Cell Activation in Streptozotocin-Induced Diabetic Rats
por: Kuthati, Yaswanth, et al.
Publicado: (2023)

Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain
por: Kuthati, Yaswanth, et al.
Publicado: (2021)

Synergistic Effect of Teneligliptin in a Case of New-Onset Bullous Pemphigoid Post Covid-19 Infection
por: Pareek, Sumiti, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bqr5bsoocvmh8bv50hc4toaol